Patent application number | Description | Published |
20080255136 | PYRROLIDONES WITH ANTI-HIV ACTIVITY - The present invention relates to inhibition of viruses, e.g., HIV using pyrrolidones and compounds related to pyrrolidones. The invention further relates to methods for identifying and using agents, including small molecule chemical compositions that inhibit HIV in a cell; as well as to methods of prophylaxis, and therapy related to HIV infection and related disease states such as AIDS. | 10-16-2008 |
20080287516 | Phenyl-Substituted Pyrrolidones - The present invention relates to phenyl-substituted pyrrolidones and compounds related to phenyl-substituted pyrrolidones. One use of these compounds is for the inhibition of viruses, e.g., HIV. The invention further relates to methods of malting these compounds, methods of identifying the efficacy of these compounds, and methods of using these compounds to inhibit or prevent HIV infection and related disease states such as AIDS. | 11-20-2008 |
20090075996 | HETEROTETRACYCLIC COMPOUNDS AS TPO MIMETICS - The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated TPO activity, particularly diseases or disorders that involve thrombocytopenia. | 03-19-2009 |
20090137570 | INHIBITORS OF CATHEPSIN S - The present invention provides compounds, compositions and methods for the selective inhibition of cathepsin S. In a preferred aspect, cathepsin S is selectively inhibited in the presence of at least one other cathepsin isozyme. The present invention also provides methods for treating a disease state in a subject by selectively inhibiting cathepsin S. | 05-28-2009 |
20090163512 | Spiroindolinone Derivatives - There are provided compounds of the formula | 06-25-2009 |
20090203681 | NOVEL N-(2-AMINO-PHENYL)-AMIDE DERIVATIVES - The present invention provides novel compounds of the general formula (I) | 08-13-2009 |
20090312321 | COMPOSITIONS AND METHODS FOR FGF RECEPTOR KINASES INHIBITORS - Described are compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat or prevent disease or disordered associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activity of kinases such as Abl, ALK, AMPK, Aurora, Axl, Bcr-Abl, BIK, Bmx, BRK, BTK, c-Kit, CSK, cSrc, CDK1, CHK2, CK1, CK2, CaMKII, CaMKIV, DYRK2, EGFR, EphB1, FES, FGFR1, FGFR2, FGFR3, Flt1, Flt3, FMS, Fyn, GSK3β, IGF-1R, IKKα, IKKβ, IR, IRAK4, ITK, JAK2, JAK3, JNK1α1, JNK2α, KDR, Lck, LYN, MAPK1, MAPKAP-K2, MEK1, MET, MKK4, MKK6, MST2, NEK2, NLK, p70S6K, PAK2, PDGFR, PDGFRα, PDK1, Pim-2, Plk3, PKA, PKBα, PKCα, PKCtheta, PKD2, c-Raf, RET, ROCK-I, ROCK-II, Ron, Ros, Rsk1, SAPK2a, SAPK2b, SAPK3, SAPK4, SGK, SIK, Syk, Tie2, TrkB, WNK3, and ZAP-70. | 12-17-2009 |
20100016368 | AMINOTETRAHYDROINDAZOLOACETIC ACIDS - The invention is concerned with the compounds of formula I: | 01-21-2010 |
20100016369 | AMINOTETRAHYDROINDAZOLOACETIC ACIDS - The invention is concerned with the compounds of formula I: | 01-21-2010 |
20100016379 | Terephthalamate Compounds and Compositions, and Their Use as HIV Integrase Inhibitors - Described herein are compounds having a terephthalamate structural feature. Also described herein, are methods of making such compounds, methods of using such compounds to modulate the activity of HIV integase, and pharmaceutical compositions and medicaments comprising such compounds. Also described herein are methods of using such compounds, pharmaceutical compositions and medicaments to treat and/or prevent and/or inhibit and/or ameliorate the pathology and/or symptomology of AIDS or infection with HIV. | 01-21-2010 |
20100041714 | BI-ARYL AMINOTETRALINES - The invention is concerned with the compounds of formula I: | 02-18-2010 |
20100081656 | COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS - The invention provides compounds and pharmaceutical compositions thereof, which are useful as protein kinase inhibitors, as well as methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated kinase activity. In some embodiments, the invention provides methods for using such compounds to treat, ameliorate or prevent diseases or disorders that involve abnormal activation of c-kit, PDGFRα, PDGFRβ, CSF1R, Abl, BCR-Abl, CSK, JNK1, JNK2, p38, p70S6K, TGFβ, SRC, EGFR, trkB, FGFR3, FLT3, Fes, Lck, Syk, RAF, MKK4, MKK6, SAPK2β, BRK, KDR, c-raf or b-raf kinase, or mutant forms thereof. | 04-01-2010 |
20100125058 | NAPHTHYLACETIC ACIDS - The invention is concerned with the compounds of formula I: | 05-20-2010 |
20100204200 | INHIBITORS OF CATHEPSIN S - The present invention provides compounds, compositions and methods for the selective inhibition of cathepsin S. In a preferred aspect, cathepsin S is selectively inhibited in the presence of at least one other cathepsin isozyme. The present invention also provides methods for treating a disease state in a subject by selectively inhibiting cathepsin S. More particularly, the present invention provides compounds having Formula 1: | 08-12-2010 |
20100234376 | [4,5']Bipyrimidinyl-6,4'-Diamine Deriviatives as Protein Kinase Inhibitors - The invention provides a novel class of compounds of the Formula I: | 09-16-2010 |
20110144106 | NOVEL CYCLOPROPANE INDOLINONE DERIVATIVES - The present invention relates to a compound of formula (I) | 06-16-2011 |
20120004218 | NOVEL TETRAHYDRO-QUINOLINE DERIVATIVES - A compound of formula (I) | 01-05-2012 |
20120095053 | AMINOTETRAHYDROINDAZOLOACETIC ACIDS - The invention is concerned with the compounds of formula I: | 04-19-2012 |
20120101131 | Aminotetrahydroindazoloacetic Acids - The invention is concerned with the compounds of formula I: | 04-26-2012 |
20130102604 | NOVEL CYCLOPROPANE INDOLINONE DERIVATIVES - The present invention relates to a compound of formula (I) | 04-25-2013 |
20150065667 | SUPPORTED METAL OXIDE DOUBLE ACTIVE CENTER POLYETHYLENE CATALYST, PROCESS FOR PREPARING THE SAME AND USE THEREOF - The present invention relates to a supported hybrid vanadium-chromium-based catalyst, characterized in the catalyst is supported on a porous inorganic carrier and a V active site and a inorganic Cr active site are present on the porous inorganic carrier at the same time. The present invention further relates to a process for producing a supported hybrid vanadium-chromium-based catalyst. The invention also provides the preparation method of the catalyst, titanium or fluorine to compounds, vanadium salt and chromium salt according to the proportion, different methods of sequence and load on the inorganic carrier, after high temperature roasting, still can further add organic metal catalyst promoter prereduction activation treatment on it. The catalyst of the present invention can be used for producing ethylene homopolymers and ethylene/α-olefin copolymers. The hybrid vanadium-chromium-based catalyst can have high activity and produce polyethylene polymers having the properties of broad molecular weight distribution (Part of the products are bimodal distribution) and excellent α-olefin copolymerization characteristic. | 03-05-2015 |